

Resource Summary Report

Generated by NIF on Jul 28, 2026

Brilliant Violet 510(TM) anti-human CD45

RRID:AB_2561940

Type: Antibody

Proper Citation

BioLegend Cat# 304036, RRID:AB_2561940

Antibody Information

URL: http://antibodyregistry.org/AB_2561940

Proper Citation: BioLegend Cat# 304036, RRID:AB_2561940

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-human CD45

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: Clone HI30

Antibody ID: AB_2561940

Vendor: BioLegend

Catalog Number: 304036

Alternative Catalog Numbers: 304035

Record Creation Time: 20250820T005525+0000

Record Last Update: 20250820T093327+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-human CD45.

No alerts have been found for Brilliant Violet 510(TM) anti-human CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Marchand V, et al. (2025) Monocytes generated by interleukin-6-treated human hematopoietic stem and progenitor cells secrete calprotectin that inhibits erythropoiesis. *iScience*, 28(1), 111522.

Newsome RC, et al. (2025) Microbial-derived immunostimulatory small molecule augments anti-PD-1 therapy in lung cancer. *Cell reports. Medicine*, 102519.

Schweihofer V, et al. (2025) Multiplexed immune profiling and 3D co-culture assays to assess the individual checkpoint therapy response in head and neck squamous cell carcinoma. *Frontiers in oncology*, 15, 1622008.

Papadimitriou TI, et al. (2025) CD8+ T cells drive myofibroblast activation and contraction via JAK/STAT3 and TGF β signaling. *iScience*, 28(12), 113904.

Ravi VR, et al. (2025) Lung CD4+ resident memory T cells use airway secretory cells to stimulate and regulate onset of allergic airway neutrophilic disease. *Cell reports*, 44(3), 115294.

Baiu DC, et al. (2025) CD8+ T cell antitumor immunity via human iNKT-DC conjugates. *Cancer immunology research*.

Albert V, et al. (2024) HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice. *International journal of molecular sciences*, 25(13).

Giovenzana A, et al. (2024) Fat-to-blood recirculation of partially dysfunctional PD-1+CD4 Tconv cells is associated with dysglycemia in human obesity. *iScience*, 27(3), 109032.

Bruss C, et al. (2024) Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative - specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy. *Frontiers in immunology*, 15, 1355130.

Wang Y, et al. (2024) Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. *Cell reports. Medicine*, 5(6), 101580.

Pettinella F, et al. (2024) Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors. *Cell reports. Medicine*, 5(2), 101380.

Li S, et al. (2023) Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells. *Cell reports*, 42(3), 112241.

Long J, et al. (2023) A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment. *Cell reports. Medicine*, 4(11), 101286.

Tang F, et al. (2023) A pan-cancer single-cell panorama of human natural killer cells. *Cell*, 186(19), 4235.

Ito R, et al. (2022) Efficient differentiation of human neutrophils with recapitulation of emergency granulopoiesis in human G-CSF knockin humanized mice. *Cell reports*, 41(12), 111841.

Tsuzuki H, et al. (2022) Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model. *Oncotarget*, 13, 1359.

Gbyli R, et al. (2022) In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. *Leukemia*, 36(5), 1313.

Affo S, et al. (2021) Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. *Cancer cell*, 39(6), 866.

Grant RA, et al. (2021) Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. *Nature*, 590(7847), 635.

Kosti P, et al. (2021) Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. *Cell reports. Medicine*, 2(4), 100227.